Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen

Rapport Therapeutics (NASDAQ:RAPP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research analysts have also weighed in on RAPP. HC Wainwright upped their target price on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Citizens Jmp raised their price objective on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Wells Fargo & Company started coverage on shares of Rapport Therapeutics in a research report on Monday, February 2nd. They issued an “overweight” rating and a $43.00 target price for the company. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Rapport Therapeutics Stock Up 6.0%

RAPP stock opened at $27.09 on Friday. The company has a 50 day moving average of $28.40 and a two-hundred day moving average of $24.56. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -10.00 and a beta of 1.63. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, research analysts anticipate that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Transactions at Rapport Therapeutics

In related news, insider Krishnaswamy Yeleswaram sold 2,840 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $85,342.00. Following the completion of the sale, the insider directly owned 296,991 shares of the company’s stock, valued at approximately $8,924,579.55. This represents a 0.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Bredt sold 8,500 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $26.84, for a total transaction of $228,140.00. Following the completion of the transaction, the insider owned 395,575 shares in the company, valued at $10,617,233. The trade was a 2.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 67,655 shares of company stock worth $1,863,705. 13.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new stake in Rapport Therapeutics in the 3rd quarter valued at approximately $43,000. Strs Ohio boosted its position in shares of Rapport Therapeutics by 23.5% in the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after acquiring an additional 400 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after acquiring an additional 4,582 shares during the period. Finally, Creative Planning acquired a new position in Rapport Therapeutics during the 2nd quarter valued at $121,000.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.